Chiltern Acquires Japanese CRO
Chiltern has acquired Integrated Development Associates (IDA), a Japanese CRO specializing in integrating Japan and Asia into global drug development.
Chiltern has acquired Integrated Development Associates (IDA), a Japanese CRO specializing in integrating Japan and Asia into global drug development. Under this acquisition, IDA will do business as a subsidiary of Chiltern and be renamed IDA, a Chiltern Company.
Read the full release here
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
